Cybin Company Presentation

P r i v a t e & C o n f i d e n t i a l 32 Financial Projections (1) (2) Key Assumptions: • Financial projections assume $0 revenue from Serenity Life Sciences Inc. (the psychedelic division). Serenity expenses and capex are accounted for. • Average MSRP for Journey products is assumed at ~C$45. • Average cost per unit for Journey products is assumed at ~C$13. • Customer acquisition is based on management’s experience using online / targeted advertising. (in C$ millions unless otherwise noted) (3) 2020E 2021E 2022E Revenue $0.4 $28.1 $61.2 COGS ($0.2) ($10.7) ($23.3) Gross Profit $0.3 $17.4 $37.9 Gross Margin 62.0% 62.0% 62.0% SG&A ($2.9) ($10.4) ($15.6) Operating Income (4) ($2.6) $7.0 $22.4 R&D (Including Clinical Trials) ($2.1) ($3.9) ($2.8) EBITDA ($4.7) $3.1 $19.6 CAPEX ($0.5) ($0.7) $0.0 (3) All financial information presented is based on a calendar year end. Cybin's fiscal year end is March 31. (4) Operating income excludes R&D spent on drug development and clinical trials. (1) Forward-looking statements and future orientated financial information are subject to various risks and assumptions, see "Cautionary Statement" on page 2 of this presentation. (2) These projections contain certain non-IFRS financial measures. These measures include EBITDA and gross margin. These measures do not have standardized meaning prescribed by IFRS and therefore are unlikely to be comparable to the calculation of similar measures used by other companies and should not be viewed as alternatives to financial measures calculated in accordance with IFRS. $0.4 $28.1 $61.2 ($2.6) $7.0 $22.4 ($4.7) $3.1 $19.6 2020E 2021E 2022E Revenue Operating Income EBITDA Launch in the second half of 2020 will be a ‘soft launch’ used to optimize targeted advertisements, customer acquisition costs, influencer marketing, etc.